Keyphrases
Adalimumab
100%
Alternative Dosing
25%
American College of Rheumatology
25%
Body Surface Area
25%
Characteristic-based
25%
Childhood Arthritis
100%
Clinical Outcomes
100%
Confounding by Indication
25%
Dose-response Relationship
25%
Etanercept
100%
Fat-free Mass
50%
Follow-up Data
25%
Ideal Body Weight
50%
Increased Dose
25%
Juvenile Arthritis Disease Activity Score
25%
Lean Body Mass
50%
Logistic Regression Model
25%
Negative Association
25%
Pediatric
25%
Registry Study
100%
Research Partnerships
100%
Residual Confounding
25%
Rheumatology Research
100%
Risk Factors
50%
Start of Treatment
25%
Systemic Juvenile Idiopathic Arthritis (sJIA)
100%
Treatment Outcome
25%
Treatment Response
75%
Tumour Necrosis Factor Inhibitor (TNFi)
75%
Nursing and Health Professions
Adalimumab
100%
Arthritis
100%
Body Weight
60%
Clinical Outcome
100%
Disease Activity Score
20%
Etanercept
100%
Fat Free Mass
40%
Ideal Body Weight
40%
Juvenile Rheumatoid Arthritis
100%
Lean Body Weight
40%
Logistic Regression Analysis
20%
Rotigotine
20%
Surface Area
20%
Treatment Outcome
20%
Treatment Response
60%
Tumor Necrosis Factor
40%
Tumor Necrosis Factor Inhibitor
20%
Immunology and Microbiology
Adalimumab
100%
Body Surface
20%
Body Weight
60%
Childhood Arthritis
100%
Etanercept
100%
Fat Free Mass
40%
Ideal Body Weight
40%
Juvenile Idiopathic Arthritis
100%
Lean Body Weight
40%
Surface Area
20%
TNF Inhibitor
20%
Tumor Necrosis Factor
40%
Biochemistry, Genetics and Molecular Biology
Adalimumab
100%
Body Weight
100%
Etanercept
100%
Fat Free Mass
66%
Ideal Body Weight
66%
Lean Body Weight
66%
Surface Area
33%
TNF Inhibitor
33%
Tumor Necrosis Factor
66%
Agricultural and Biological Sciences
Adalimumab
100%
Americans
33%
Body Weight
100%
Ideal Body Weight
66%
Lean Body Mass
66%
Risk Factor
66%
Surface Area
33%
TNF Inhibitor
33%
Tumor Necrosis Factor
66%
Pharmacology, Toxicology and Pharmaceutical Science
Adalimumab
100%
Arthritis
100%
Disease Activity Score
20%
Etanercept
100%
Juvenile Rheumatoid Arthritis
100%
Rotigotine
20%
Tumor Necrosis Factor
40%
Tumor Necrosis Factor Inhibitor
20%